Ask AI
ASCO 2025 Gastrointestinal Cancers

CE / CME

Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the ASCO 2025 Annual Meeting

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: July 11, 2025

Expiration: January 10, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following findings was reported from the phase III ATOMIC trial comparing adjuvant mFOLFOX6 + atezolizumab with mFOLFOX6 alone in patients with resected stage III dMMR colon cancer?

2.

In your practice, which of the following would you recommend as second-line therapy for a patient with HER2-positive advanced gastric cancer following progression on trastuzumab + chemotherapy and a goal of maximizing survival based on results from the DESTINY-Gastric04 phase III trial that compared ramucirumab + paclitaxel with trastuzumab deruxtecan? For this patient, you have also confirmed that the tumor still overexpresses HER2.

3.

Satri-cel, a novel CAR T-cell therapy, demonstrated a significant improvement in PFS in previously treated patients with advanced gastric/GEJC who were selected for which of the following biomarkers?